Anti-Amyloid Beta Vaccine Candidate for Alzheimer’s Shows Positive Study Results

AC Immune SA today announced the first interim safety, tolerability, and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta (Abeta) vaccine ACI-24.060 in patients with prodromal Alzheimer's disease (AD). 

Early results from the first cohort of AD patients in ABATE showed that low dose ACI-24.060 could elicit an anti-Abeta antibody response as soon as week 6 (2 weeks after the second injection).

The data show that ACI-24.060 vaccination has been safe and well tolerated to date.

As a result, dosing in ABATE's second, higher-dose AD cohort has begun, and the trial is cleared to start screening specific individuals for part 2 of the study.

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented in a press release on January 26, 2023, "We are delighted with the encouraging initial safety, and immunogenicity findings for ACI-24.060 in ABATE reported today."

"We believe ACI-24.060's successful development could provide patients with a novel therapeutic option offering numerous potential advantages in treatment, maintenance, and prevention settings."

"These early findings from ABATE represent an important step towards this goal, and we look forward to reporting more detailed data at a future conference."

ACI-24.060, derived from AC Immune's SupraAntigen® platform, has been shown in preclinical studies to induce a strong polyclonal antibody response that matures and is maintained against oligomeric and pyroglutamate-Abeta species, essential pathological forms of Abeta believed to drive Abeta plaque formation and disease progression.

Targeting Abeta using antibodies has recently been validated with U.S. FDA approvals of new monoclonal antibody treatments for patients with AD.

By eliciting polyclonal anti-Abeta antibodies, the ACI-24.060 anti-Abeta vaccine development program aims to ultimately deliver significant benefits to patients, their caregivers, and healthcare systems regarding potential safety and tolerability, low-frequency dosing, low overall costs, and durable responses.